Supernus Pharmaceuticals/SUPN

$29.40

1.83%
-
1D1W1MYTD1YMAX

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Ticker

SUPN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jack Khattar

Employees

652

Headquarters

Rockville, United States

SUPN Metrics

BasicAdvanced
$1.59B
Market cap
-
P/E ratio
-$0.02
EPS
1.02
Beta
-
Dividend rate
$1.59B
1.02074
$39.09
$21.99
402.47K
1.699
1.433
15.553
0.09%
0.15%
0.13%
2.613
1.722
7.758
14.36
-8.95%
-101.45%
5.3%
-78.44%

What the Analysts think about SUPN

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
37.76% upside
High $43.00
Low $38.00
$29.40
Current price
$40.50
Average price target

SUPN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.66% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$164.3M
6.83%
Net income
$1.1M
-106.92%
Profit margin
0.66%
-106.39%

SUPN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 60.84%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.70
$0.49
$0.24
$0.89
-
Expected
$0.17
$0.07
$0.08
$0.55
$0.38
Surprise
311.76%
653.85%
200%
60.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals (SUPN) has a market cap of $1.58B as of April 21, 2024.

What is the P/E ratio for Supernus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 0 as of April 21, 2024.

Does Supernus Pharmaceuticals stock pay dividends?

No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Supernus Pharmaceuticals dividend payment date?

Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.

What is the beta indicator for Supernus Pharmaceuticals?

Supernus Pharmaceuticals (SUPN) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Supernus Pharmaceuticals stock price target?

The target price for Supernus Pharmaceuticals (SUPN) stock is $40.5, which is 37.76% above the current price of $29.4. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Supernus Pharmaceuticals stock

Buy or sell Supernus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing